1. Why Cancer?

   • Alan Haycox

   Editorial Open access 18 May 2016 Pages: 625 - 627

2. Cancer Drugs Fund 2.0: A Missed Opportunity?

   • Christopher McCabe
   • Ash Paul
   • Mike Paulden

   Commentary 22 March 2016 Pages: 629 - 633

3. Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine

   • Gregory S. Zaric

   Current Opinion 22 February 2016 Pages: 635 - 644

   

4. Health, Health-Related Quality of Life, and Quality of Life: What is the Difference?

   • Milad Karimi
   • John Brazier

   Current Opinion 18 February 2016 Pages: 645 - 649

5. Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches

   • James Shearer
   • Paul McCrone
   • Renee Romeo

   Practical Application 27 February 2016 Pages: 651 - 664

6. Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics

   • J. Jaime Caro

   Practical Application 09 March 2016 Pages: 665 - 672

   

7. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Hazel Squires
   • Matt Stevenson
   • John Stevens

   Review Article 18 February 2016 Pages: 673 - 680

   

8. Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease

   • Luis Hernandez
   • Asli Ozen
   • Denis Getsios

   Systematic Review 22 February 2016 Pages: 681 - 707

   

9. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

   • Krithika Rajagopalan
   • David Trueman
   • Antony Loebel

   Original Research Article Open access 11 April 2016 Pages: 709 - 721